Eli Lilly company profile
Company profile
Eli Lilly has 50,000 employees and is headquartered in Indianapolis, United States.
Insulin brands Humalog and Humulin, together with the diabetes and obesity medicines Mounjaro, Trulicity and Zepbound, are among the best-known products of Eli Lilly and Company. The group also sells cancer treatments such as Verzenio, Jaypirca and Erbitux, immunology drugs including Taltz and Omvoh, and Kisubla for symptomatic Alzheimer's disease. Its prescription medicines reach customers in the United States, Europe, China, Japan and other markets worldwide, and the company works with partners such as Boehringer Ingelheim on the Jardiance family.
In the fiscal year ended December 2025, revenue reached 65.2 billion US dollars, up 44.7% from the previous year, and net income was 20.6 billion dollars. The United States generated 66.7% of revenue and Europe 17.7%. The company had 50,000 employees, is headquartered in Indianapolis, Indiana, and was founded in 1876.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Headquarters
- Lilly Corporate Center, 46285, Indianapolis
- Employees
- 50,000
- Chief executive
- David Ricks
- Founded
- 1876
- Fiscal year
- January - December
- Listing
- LLY · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US5324571083
- Website
- lilly.com
Eli Lilly and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Eli LillyLLY | United States | $1.29T | 50,000 | 51.3% | 46.9 |
| Johnson & JohnsonJNJ | United States | $687.89B | 138,200 | 26.6% | 43.4 |
| AbbVieABBV | United States | $521.5B | 57,000 | 36.6% | 50.6 |
| Merck & Co.MRK | United States | $364.26B | 73,000 | 35.2% | 147.8 |
| AmgenAMGN | United States | $251.89B | 31,500 | 34.1% | 27.0 |
| Gilead SciencesGILD | United States | $208.48B | 17,000 | 38.2% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
